Print Page | Contact Us | Sign In
News & Press: FDA

Restrictions to prevent the use of Valproate medicines in women and girls of childbearing potential

Thursday, 14 March 2019   (0 Comments)
Share |

The latest release from the Food and Drugs Authority (FDA) seeks to bring to the attention of healthcare professionals the restrictions and measures to prevent valproate exposure during pregnancy because babies exposed in utero to valproate are at high risk of serious developmental disorders (in up to 30-40% of cases) and/or congenital malformations (in approximately 10% of cases).

The full correspondence from the FDA can be downloaded here.